Brokerages Set Vericel Co. (NASDAQ:VCEL) Price Target at $57.71

Vericel Co. (NASDAQ:VCEL) has been assigned an average rating of “Buy” from the seven brokerages that are currently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have issued a report on the stock in the last year is $58.14.

A number of equities analysts have recently commented on VCEL shares. TD Cowen boosted their price target on Vericel from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, August 27th. Canaccord Genuity Group reissued a “buy” rating and issued a $60.00 target price on shares of Vericel in a report on Tuesday, November 19th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Stephens upped their price objective on shares of Vericel from $56.00 to $58.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Canaccord Genuity Group started coverage on shares of Vericel in a research report on Friday, August 9th. They issued a “buy” rating and a $57.00 target price on the stock.

Vericel Stock Up 4.2 %

Shares of Vericel stock opened at $59.11 on Tuesday. The firm’s 50-day moving average price is $46.13 and its two-hundred day moving average price is $47.00. The company has a market capitalization of $2.92 billion, a price-to-earnings ratio of 985.33 and a beta of 1.66. Vericel has a 12-month low of $32.31 and a 12-month high of $60.15.

Vericel (NASDAQ:VCEL) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.03. Vericel had a net margin of 1.56% and a return on equity of 1.48%. The business had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. On average, sell-side analysts expect that Vericel will post 0.13 earnings per share for the current year.

Insider Buying and Selling at Vericel

In other Vericel news, Director Steven C. Gilman sold 5,833 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $40.35, for a total value of $235,361.55. Following the sale, the director now owns 11,000 shares in the company, valued at approximately $443,850. The trade was a 34.65 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Dominick Colangelo sold 17,500 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total value of $724,150.00. Following the transaction, the chief executive officer now owns 220,937 shares of the company’s stock, valued at $9,142,373.06. This trade represents a 7.34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,166 shares of company stock worth $1,200,764. 5.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of VCEL. International Assets Investment Management LLC raised its stake in Vericel by 4,126.7% during the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares during the last quarter. CWM LLC raised its position in shares of Vericel by 319.0% in the 2nd quarter. CWM LLC now owns 662 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 504 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Vericel by 48.1% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Vericel by 22.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares in the last quarter. Finally, Meeder Asset Management Inc. bought a new stake in shares of Vericel during the 3rd quarter valued at about $92,000.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.